HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EWG Seeks Realistic FDA Review Deadlines In Sunscreen Innovation Act

This article was originally published in The Tan Sheet

Executive Summary

While the Environmental Working Group supports the Sunscreen Innovation Act, it would like to see realistic deadlines put in place to accelerate FDA’s review of sunscreen-ingredient time-and-extent applications without including a default mechanism that would grant free market access to certain sunscreen actives when FDA fails to act within allotted timeframes.

You may also be interested in...



Dingell Pushes Sunscreen TEA Changes As Sun Sets On His Career

The longest-serving member of Congress says he is committed to working with members of both parties to approve the Sunscreen Innovation Act “in whatever bipartisan manner is necessary so it can be signed into law this year.”

FDA Sunscreen Decision Deadlines, Expedited TEAs Proposed

The Sunscreen Innovation Act, introduced in both the House and the Senate, would streamline the process for FDA review of sunscreen TEAs and impose deadlines for agency action.

Women’s Voices For The Earth Will Keep After CIR, Salon Worker Safety In 2024

Women’s Voices for the Earth continues to call attention to cosmetic ingredients’ potential health impacts on users including salon workers, while pushing the Cosmetic Ingredient Review to consider a wider variety of safety information in its assessment work.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS139412

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel